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Introduction
 Diabetes mellitus is a disease state of chronic hyperglycemia caused by insulin resistance 
and decreased insulin secretion. It is characterized by  a loss in pancreatic islet  β-cell mass and 
function (Doria, Patti et al. 2008). As of 2011, 347 million people worldwide suffered from 
diabetes mellitus (Danaei, Finucane et al. 2011). In the United States, the disease is the seventh 
leading cause of death, and it increases the risk of other health complications, including 
cardiovascular disease, stroke, neuropathy, retinopathy, and kidney failure (Morrish, Wang et al. 
2001; Alwan, Armstrong et al. 2011; CDC 2011; WHO 2012).
 There are two main types of diabetes. Type 2 diabetes, termed adult onset  or non-insulin-
dependent diabetes, comprises the vast majority  of cases of diabetes (WHO 1999; Kriketos, 
Greenfield et al. 2004). Due to a combination of genetic factors, obesity, and a sedentary 
lifestyle, type 2 diabetes results in progressive β-cell failure, which leads to a decline in β-cell 
mass and function and results in deficient insulin secretion and increasing insulin resistance 
(Kriketos, Greenfield et al. 2004; Alexandraki, Piperi et al. 2006). This loss of β-cell viability is 
thought to be exacerbated by  a cytokine-related systemic inflammation, which has previously 
been linked to the development of type 1 diabetes (Alexandraki, Piperi et al. 2006).
 Type 1 diabetes, formerly  called juvenile onset  or insulin-dependent diabetes, comprises 
the minority of diabetes cases and is mostly diagnosed in individuals younger than 18 years of 
age (WHO 1999; Kriketos, Greenfield et  al. 2004). It is characterized by absolute insulin 
deficiency due to autoimmune-mediated selective destruction of insulin-producing β-cells 
(Kriketos, Greenfield et al. 2004; Eizirik, Colli et al. 2009). This autoimmune-induced diabetes is 
thought to be associated with the release of chemotactic cytokines, or chemokines. Cytokines are 
a group of pharmacologically  active proteins that affect the inflammatory and immune systems 
by autocrine and paracrine modes of action, and chemokines are a family  of small cytokines that 
induce leukocyte migration to sites of injury via cellular chemotaxis (Fernandez and Lolis 2002; 
Alexandraki, Piperi et al. 2006). Cytokines and chemokines, especially  those secreted from 
adipose tissue, trigger an immune cell invasion of pancreatic islets via inflammatory  signaling 
pathways (Alexandraki, Piperi et al. 2006; Deshmane, Kremlev et al. 2009).
 One such chemokine involved in this process is monocyte chemoattractant protein-1, or 
CCL2. CCL2 is responsible for the recruitment of leukocytes, monocytes, macrophages, and T-
cells to islet tissues and the subsequent release of toxic pro-inflammatory cytokines, such as 
IL-1β (Hayden and Ghosh 2008; Deshmane, Kremlev et al. 2009; Oeckinghaus, Hayden et al. 
2011). IL-1β is an inflammatory, cytotoxic cytokine that decreases β-cell function and viability. 
Along with IL-6, IL-1β increases the risk of developing diabetes by  inhibiting β-cell function and 
inducing β-cell death via autoimmune destruction (Alexandraki, Piperi et al. 2006). 
 The increased expression of pro-inflammatory cytokines in peripheral blood mononuclear 
cells occurs with an increase in pro-inflammatory genes transcription regulated by nuclear factor-
κB, or NF-κB (Alexandraki, Piperi et al. 2006). In non-stimulated cells, the latent dimer form of 
NF-κB and its subunits, including p65 and p50, are bound to IκB, an NF-κB inhibitor, and its 
corresponding subunits (Devaraj, Dasu et al. 2010). Upon stimulation by  cytokines, IκBα is 
phosphorylated and effectively degraded, allowing NF-κB subunits, such as p65 (Rel A) and p50, 
to accumulate in the nucleus. These major protein components of NF-κB affect gene expression 
by binding κB elements in specific gene promoters and increasing the synthesis and secretion of 
monocyte chemokines and cytokines (Alexandraki, Piperi et al. 2006; Devaraj, Dasu et al. 2010). 
Through this NF-κB pro-inflammatory  signaling pathway, cytokines are able to regulate the 
transcription of a number of genes related to β-cell death, including that of CCL2 (Hayden and 
Ghosh 2008; Oeckinghaus, Hayden et al. 2011). The over-expression of these pro-inflammatory 
cytokines results in an increase in β-cell impairment and destruction, insulitis, and eventual 
diabetes (Alexandraki, Piperi et al. 2006; Martin, Rankin et  al. 2008; Ogliari, Caldara et al. 
2008).
 While the inflammatory  signaling pathways regulating CCL2 expression in pancreatic 
islets are not completely understood, therapeutic drugs with anti-inflammatory actions are 
frequently used in diabetes to decrease inflammation (Biju, McCormick et al. 2011). Among 
these are glucocorticoids, a class of catabolic steroid hormones known to regulate glucose 
synthesis and metabolism (Netter 1965). Synthesis and release of glucocorticoids is regulated by 
the hypothalamic-pituitary-adrenal axis, and serum levels vary by circadian rhythm and elevate 
in response to physical and psychological stresses (Clark and Belvisi 2012). Glucocorticoids 
work through both genomic and non-genomic mechanisms to suppress pro-inflammatory 
pathways and promote anti-inflammatory  pathways. Through binding action with the 
glucocorticoid receptor (GR), glucocorticoids can form a GR dimer that uncovers a zinc finger 
DNA-binding site attached to a glucocorticoid response element (GRE), regulating specific 
target genes and suppressing the NF-κB pathway  (Rhen and Cidlowski 2005; Witchel and 
DeFranco 2006; De Bosscher and Haegeman 2009). The receptor can also interact with 
coregulator proteins, controlling transcriptional activation or repression without direct interaction 
with DNA (Witchel and DeFranco 2006). The coordinated regulation of a diverse number of 
target genes within the cell promotes an anti-inflammatory state that offsets the toxic effects of 
pro-inflammatory pathways (Witchel and DeFranco 2006; De Bosscher and Haegeman 2009).
 The most abundant naturally-occurring 
glucocorticoids are the adrenocortical hormones 
cortisol and cortisone (Netter 1965; Davis 1981). 
Cortisol is the active form of cortisone, and it 
plays an important regulatory role in the 
metabolism of macronutrients and electrolytes 
(Davis 1981). Derived from cholesterol, both 
steroid hormones are synthesized principally in 
the zona fasciculata of the adrenal cortex, though 
synthesis also occurs in areas such as the primary 
lymphoid organs, intestines, skin, and central 
nervous system (Clark and Belvisi 2012). Cortisol 
is referred to pharmaceutically as hydrocortisone 
and is commonly used as an anti-inflammatory 
agent (Davis 1981). 
 Hydrocortisone-derived synthetic glucocorticoids can possess improved glucocorticoid 
receptor affinity, nuclear receptor selectivity, or an increased duration of action as compared to 
endogenous hydrocortisone, increasing their anti-inflammatory efficacy (Biju, McCormick et al. 
2011; Gilman, Goodman et al. 1980). Figure 1 shows the basic structure of cortisol and the 
points of modification determining the characteristics of synthetic compounds. Structures 
necessary  for the characteristic anti-inflammatory and carbohydrate-regulating effects of 
adrenocorticosteroids include: the 4,5 double bond, the 3-ketone, and the 11-hydroxyl group 
(Gilman, Goodman et al. 1980). Points of modification, shown in bold in Figure 1, can yield a 
variety of compounds with different characteristics. For example, the addition of a 1,2 double 
bond, seen in prednisolone and prednisone derivatives of cortisone and cortisol respectively, 
improves anti-inflammatory effects and enhances the ratio of carbohydrate-regulating potency to 
sodium-retaining potency (Gilman, Goodman et al. 1980). The 17α-hydroxy group  is the main 
differentiator between cortisol and corticosterone, and it lends to the full expression of anti-
inflammatory and carbohydrate-regulating effects of cortisol. Finally, the 21-hydroxy group, 
found in all natural corticosteroids and most synthetic forms, is required for significant sodium-
retaining activity and some glycogenic and anti-inflammatory activities (Gilman, Goodman et al. 
1980).
Figure 1: Structure-function relationship in 
adrenocorticosteroids. Bold structures 
indicate modification points for synthetic 
derivatives. Source: Gilman 1980
 Among the most commonly used synthetically-derived glucocorticoids are prednisolone, 
dexamethasone, and fluticasone propionate (Biju, McCormick et al. 2011). Prednisolone, shown 
in Figure 2, has increased anti-inflammatory efficacy as well as a slower relative metabolism 
compared to cortisol (Gilman, Goodman et al. 1980). Dexamethasone, or 9α-Fluoro-16α-methyl 
prednisolone, is shown in Figure 3. With no sodium-retaining potency, dexamethasone has a long 
duration of action and a much greater relative anti-inflammatory  effect, requiring a much lower 
equivalent dose as compared to cortisol (Gilman, Goodman et  al. 1980). This potent synthetic 
glucocorticoid is used to suppress endogenous release of cortisol and adrenocorticotropic 
hormone and is used treat  a variety of inflammatory-based disorders ranging from acute injury  to 
organ function to certain types of cancer (Nussey  and Whitehead 2001; Petrella, Ercolino et al. 
2006; Choi, Jo et al. 2013). Fluticasone propionate, or S-(fluoromethyl)6α,9-difluoro-11β-17-
dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate,17-propionate, is shown in 
Figure 4. Fluticasone propionate possesses strong anti-inflammatory potency, displays activity 
similar to progesterone, and has shown a glucocorticoid receptor binding and gene expression 
three to five times more potent than dexamethasone (Smith 2011). Fluticasone propionate also 
shows some affinity  for progesterone receptor binding (Issar, Sahasranaman et  al. 2006). It  has 
wide therapeutic use in nasal sprays to alleviate allergy symptoms (Smith 2011).
Figure 2: Structure of Prednisolone. 
Source: Wikipedia
Figure 3: Structure of Dexamethasone. 
Source: Wikipedia
Figure 4: Structure of Fluticasone 
Propionate. Source: Wikipedia
 Despite the anti-inflammatory  benefits of glucocorticoids, a number of systemic side 
effects can occur from overdosage or prolonged use (Schacke, Docke et al. 2002). In response to 
overexposure, the glucocorticoid receptor can experience a hormone-dependent down-regulation, 
which can alter stress responses and reduce inflammatory response. While this can be beneficial 
on a cellular level as a feedback mechanism, the change in hormonal response can have negative 
consequences on an organ system level (Witchel and DeFranco 2006). Chronic use of 
glucocorticoids can disrupt hypothalamic-pituitary-adrenal axis homeostasis and suppress its 
function, causing a wide range of adverse effects on metabolism, the cardiovascular system, and 
within the central nervous system (Clark and Belvisi 2012; Nam, Kim et al. 2013). Side effects 
from glucocorticoid use include increased susceptibility to infection, hypertension, 
neurocognitive impairment, hyperglycemia, muscle atrophy, osteoporosis, and impaired 
carbohydrate homeostasis (Gilman, Goodman et al. 1980; Witchel and DeFranco 2006; Clark 
and Belvisi 2012). Over-exposure to glucocorticoids can inhibit glucose-stimulated insulin 
secretion in the pancreas and peripheral glucose uptake in the muscles, leading to 
immunosuppression, β-cell dysfunction, and impaired glucose tolerance (Witchel and DeFranco 
2006; Nikolic, Vujicic et al. 2013).
 Compromised insulin-stimulated glucose uptake in the muscles seen in insulin resistance 
is characteristic of metabolic syndrome and Cushing’s syndrome (Witchel and DeFranco 2006). 
Metabolic syndrome, also known as insulin resistance syndrome or syndrome X, is a disorder of 
chronic pro-inflammatory activation characterized by a group of risk factors including central 
obesity, hyperglycemia, hypertension, and dyslipidemia (Witchel and DeFranco 2006; A.D.A.M. 
Medical Encyclopedia 2012). While central obesity and insulin resistance are the main risk 
factors, metabolic syndrome is also exacerbated by aging, hormonal changes, genetic 
predisposition, sedentary lifestyle, and systemic inflammation (A.D.A.M. Medical Encyclopedia 
2012). Metabolic syndrome increases the risk of cardiovascular disease, stroke, and type 2 
diabetes, and it is becoming increasingly problematic in the United States (Witchel and 
DeFranco 2006; A.D.A.M. Medical Encyclopedia 2012).
 Cushing’s syndrome is a hormonal disorder characterized by chronic exposure to 
excessive glucocorticoid levels (Witchel and DeFranco 2006; Prague, May et al. 2013). While 
hypercortisolemia can be due to endogenously rooted hormonal imbalances, Cushing’s syndrome 
is more commonly caused by prolonged use of glucocorticoid therapeutic drugs. Slowly 
progressive and non-specific in symptoms, Cushing’s syndrome patients may suffer from a 
combination of weight gain, depression, skeletomuscular weakness, and headaches. Cushing’s 
syndrome is linked to diabetes and hypertension and can cause myopathy, congestive cardiac 
failure, reproductive disfunction, osteoporosis, and mood disturbance. Untreated Cushing’s 
syndrome is linked with 50% mortality within five years (Prague, May et al. 2013).
 Cushing’s syndrome represents an archetype of metabolic syndrome, as the majority  of 
signs and symptoms are shared between the two, and effective treatment of Cushing’s syndrome 
would also improve the main symptoms of metabolic syndrome (Chanson and Salenave 2010). 
Decreasing intracellular cortisol levels is shown to improve metabolic status. Therefore, it  is 
important to understand glucocorticoid-based β-cell disfunction, as well as improve upon the 
tissue-selective action of glucocorticoids through synthesis of novel compounds that  can mimic 
the beneficial actions of cortisol without the undesirable side effects (Witchel and DeFranco 
2006).
 The transrepression of the pro-inflammatory  NF-κB pathway is thought to be the major 
anti-inflammatory  effect of glucocorticoids. The role of transactivation of genes by 
glucocorticoids, however, is disputed (Biju, McCormick et al. 2011; Clark and Belvisi 2012). 
Some studies have suggested that the majority of side effects seen in glucocorticoid use are due 
to transactivation via GR receptor-steroid dimer complex interaction with DNA. The 
transactivation properties have long been suggested to be key  in determining the metabolic side 
effects of glucocorticoids (Newton and Holden 2007). However, further studies have shown 
evidence contrary to this belief, attributing some beneficial anti-inflammatory effects to 
glucocorticoid gene transactivation as well as transrepression (Burke, Goff et al. 2012; Clark and 
Belvisi 2012). The newer studies argue that the varied and interdependent actions of 
glucocorticoids cannot be neatly divided into separate results of transactivation versus 
transrepression. In addition, glucocorticoid actions seen as undesirable side effects when over-
expressed are evolutionarily advantageous within the feedback system of endogenous 
glucocorticoids, further complicating any distinctions that may be drawn about a subset of 
glucocorticoid actions (Clark and Belvisi 2012).
 Nevertheless, efforts continue to be made to synthesize a glucocorticoid with dissociative 
properties, or one that can separate transactivation and transpression activities, in hopes of 
creating a potential therapeutic drug with improved safety profile to treat inflammatory-linked 
diseases (Biju, McCormick et al. 2011). Despite controversy surrounding dissociative modes of 
action, the synthesis of novel compounds can still yield glucocorticoids with improved anti-
inflammatory function with minimized side effects due to slight changes in transcriptional 
regulatory activity or altered pharmacological properties (Clark and Belvisi 2012). 
 Previous synthetic hydrocortisone derivatives, while effective at mimicking and 
improving upon the beneficial anti-inflammatory  functions of the endogenous hormone, also 
carry  with them the associated negative side effects. For instance, dexamethasone has shown in 
vivo to induce hyperinsulinemia and insulin resistance in a dose-dependent manner without 
notable hyperglycemia (Rafacho, Cestari et al. 2009). 
 Recently, C-21 mercapto-benzothiazole compounds (mercaptosteroids) have been 
prepared from hydrocortisone through a process described in Figure 5 (Biju, McCormick et al. 
2011). In particular, mercaptosteroids 4 and 6 from this synthesis have shown improved safety 
profiles, with mercaptosteroid 4 also demonstrating a promising dissociative profile. 
Mercaptosteroid 4 has shown moderate inhibition of IL-6 cytokine synthesis and significant 
inhibition of inflammatory cell influx as compared to fluticasone propionate. Along with 
significant in vivo anti-inflammatory activity, it has demonstrated a better safety profile. Studies 
both in vitro and in vivo focused on the therapeutic potential of mercaptosteroid 6 in asthma 
showed effective lung function preservation and suppression of pulmonary inflammation with an 
improved safety profile as compared to fluticasone propionate  (Biju, McCormick et al. 2011).
 Due to the particularly promising results of C-21 mercapto-benzothiazole compound 
(mercaptosteroid) 4 in its anti-inflammatory use within the lungs, this study  seeks to examine the 
anti-inflammatory action of this compound within the pancreatic β-cell. It is hypothesized that 
this compound will suppress the pro-inflammatory  action of the CCL2 gene without impairing β-
cell function, proving to be a potential therapeutic intervention for β-cell-related disorders.
Figure 5: Synthesis of 
Mercaptosteroids 4 and 6 from 
cortisol. Source: Biju 2011
Methods
 The cell line used in these experiments was 832/13, a rat  insulinoma (INS-1) derived cell 
line containing the human proinsulin gene that shows a more sensitive glucose response 
(Hohmeier, Mulder et al. 2000). Plasmid vectors containing a luciferase reporter gene were 
inserted into the cells. To measure transactivation, glucocorticoid response element (3XGRE) 
was the reporter gene driving luciferase. For transpression, CCL2 reporter gene drove luciferase. 
The compounds hydrocortisone and mercaptosteroid 4 used in this research were generated in 
Dr. Shawn Campagna’s organic chemistry laboratory at the University  of Tennessee Department 
of Chemistry. Compounds were each diluted from powder into dimethyl sulfoxide (DMSO), 
which were then diluted into media for application into cell culture. Dilution factors used were 
10µmol (-5), 1µmol (-6), 0.1µmol (-7), 10nmol (-8), 1nmol (-9), and 0.1nmol (-10).
 Once cells were harvested, luciferase assays were performed according to the 
manufacturer’s instructions (Promega). Following luciferase assays, bicinchoninic acid (BCA) 
assays were performed to normalize protein content of each well plate to total protein content. 
DMSO served as the vehicle control. The control IL-1β-mediated CCL2 promoter activity was 
set at 100%, and the control transactivation of synthetic glucocorticoid responsive promoter 
termed the 3XGRE was set at  1.0. Transrepression of IL-1β-mediated CCL2 promoter activity 
was measured as percent reduction in expression, while transactivation of 3XGRE was analyzed 
as fold over control. The resulting transactivation and transpression due to mercaptosteroid 4 
were compared to that of hydrocortisone.
Results
 As expected, decreased IL-1β induction of CCL2 was observed in the presence of 
hydrocortisone. For the hydrocortisone doses ranging form 0.1nmol (-10) through 1µmol (-6), 
repression of IL-1β-mediated CCL2 promoter activity was approximately 50% to 80% as 
compared to the control. For dose 10µmol (-5) IL-1β response was approximately 25% of the 
control. Mercaptosteroid 4 displayed similar transrepression capabilities. Relative to the control 
promoter activity, mercaptosteroid 4 exhibited dose-dependent repression of IL-1β induction of 
CCL2 reporter gene. By dose 1µmol (-6), IL-1β expression was less than 50% compared to the 
control. At dose 10µmol (-5), IL-1β response was approximately 25% of the control. 
 In contrast, transactivation of synthetic glucocorticoid responsive promoter 3XGRE was 
observed in hydrocortisone but not with exposure to mercaptosteroid 4. With hydrocortisone, no 
significant increase in expression over control was observed in doses 0.1nmol (-10) or 1nmol 
(-9). Expression increased 4-fold over control by dose 10nmol (-8), rose approximately 8-fold 
over control with doses 0.1µmol (-7) and 1µmol (-6), and showed transactivation of 
approximately 10-fold over control with dose 10µmol (-5). Transactivation due to 
mercaptosteroid 4 was not observed with doses 0.1nmol (-10) through 1µmol (-6). At dose 
10µmol (-5), transactivation over control increased to nearly 2-fold over control. This increase in 
expression is still less than was observed with hydrocortisone at a lower dose of 10nmol (-8).
Discussion
 Based on the observed results, mercaptosteroid 4 appears as effective as hydrocortisone at 
transpressing IL-1β-mediated CCL2 promoter activity. This indicates that mercaptosteroid 4 may 
effectively inhibit toxic pro-inflammatory  pathways in the pancreas, as CCL2 and IL-1β are 
linked with pancreatic β-cell destruction via inflammatory  responses (Alexandraki, Piperi et al. 
2006; Hayden and Ghosh 2008; Deshmane, Kremlev et al. 2009). While the specific significance 
of the presence of transactivation is still debated, the lack of transactivation of synthetic 
glucocorticoid responsive promoter 3XGRE from mercaptosteroid 4 as compared to 
hydrocortisone may be an indication that transactivation-induced side effects may not be present. 
 Overall, results suggest  that mercaptosteroid 4 could have promising potential as a 
therapeutic agent similar to hydrocortisone in type 1 diabetes mellitus. Further studies are needed 
to understand the impact of the dissociative properties of mercaptosteroid 4. Alternative 
experiments aimed at measuring undesirable side effects through other mechanisms could also be 
performed. Finally, similar studies discussed in this paper examining transrepression and 
transactivation could also be performed using mercaptosteroid 6.
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